Skip to content

Perioperative Respiratory Adverse events_sugammadex

Effect of Sugammadex Versus Neostigmine on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: a Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05354466
Enrollment
174
Registered
2022-04-29
Start date
2022-06-27
Completion date
2024-09-04
Last updated
2024-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Complication

Brief summary

Perioperative respiratory adverse events are common in children. We aimed to evaluate the effect of sugammadex on the incidence of perioperative respiratory adverse events in pediatric patients receiving tonsillectomy

Interventions

sugammadex as reversal agent

DRUGNeostigmine

neostigmine as a reversal agent

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Years to 6 Years
Healthy volunteers
No

Inclusion criteria

* Pediatric patients aged 2-6 years who were scheduled for tonsillectomy under general anesthesia were enrolled

Exclusion criteria

* a recent history of upper respiratory tract infection within 2 weeks of surgery * allergic reaction to sugammadex * renal failure * liver failure * arrhythmia

Design outcomes

Primary

MeasureTime frameDescription
Perioperative respiratory adverse eventsfrom induction of anesthesia to end of operation, about 3 hoursthe incidence of overall perioperative respiratory adverse events; oxygen desaturation \< 95%, airway obstruction, laryngospasm, bronchospasm, severe coughing, or postoperative stridor

Secondary

MeasureTime frameDescription
Cardiac arrestfrom induction of anesthesia to end of operation, about 3 hoursdocumented chest compressions/defibrillation/cardioversion
Anaphylaxisfrom induction of anesthesia to end of operation, about 3 hoursadministration of epinephrine, methylprednisolone, diphenhydramine, documented diagnosis of anaphylactic/ anaphylatoid reaction
bradycardiafrom induction of anesthesia to end of operation, about 3 hoursadministration of IV atropine, glycopyrrolate, epinephrine, ephedrine
Bronchospasmfrom induction of anesthesia to end of operation, about 3 hoursadministration of albuterol, epinephrine
Nausea and vomitingfrom induction of anesthesia to end of operation, about 3 hours
Allergic reactionfrom induction of anesthesia to end of operation, about 3 hoursredness, urticaria, wheeze

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026